Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children13910.24287/1726-1708-2016-15-4-97-102КЛИНИЧЕСКИЕ ЛАБОРАТОРНАЯ ДИАГНОСТИКАA test system for assessment of interferon gamma bioactivityТест-система для определения биоактивности интерферона-гаммаKonyaevaEkaterina P.КоняеваЕкатерина Павловна
Russian Federation
konyaeva@phystech.eduKulikovaKseniya V.КуликоваКсения Валерьевна
Russian Federation
kv.kulikova@gmail.comLukashinaMarina I.ЛукашинаМарина Игоревна
Russian Federation
mlukashina@mail.ruGnuchevNikolay V.ГнучевНиколай Васильевич
Russian Federation
gnuchev@igb.ac.ruGeorgievGeorgiy P.ГеоргиевГеоргий Павлович
Russian Federation
georgiev@igb.ac.ruLarinSergey S.ЛаринСергей Сергеевич
Russian Federation
sergei_larin@mail.ruDmitry Rogachev Federal Research Centre of Paediatric Haematology, Oncology and Immunology, Ministry of Health of the Russian FederationФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава РоссииMoscow Institute of Physics and Technology (State University)Московский физико-технический институт (государственный университет)Institute of Gene Biology, Russian Academy of SciencesИнститут биологии гена РАНN.I.Pirogov Russian National Research Medical UniversityРоссийский национальный исследовательский медицинский университет им. Н.И.ПироговаInstitute of Gene Biology, Russian Academy of Medical SciencesИнститут биологии гена РАН191220161549710219092018Copyright ©; 2016, «D. Rogachev NMRCPHOI»Copyright ©; 2016, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2016«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/139

FN-y is a cytokine of great clinical significance. The excessive or insufficient function of the signalling pathway triggered by IFN-y is a cause of various pathological states of the immune system and the body in general. At present, clinical practice uses quantitative methods of detection of this protein without taking into account its functional activity. Traditional tests for assessment of the biological activity of IFN-y are technologically complex and their results are poorly quantified. In the course of this work a model system was created representing a cell line with a reporter construct stably integrated into the genome controlled by a STAT-dependent promotor. Processing of the cells of this model system by IFN-y activates the STAT-1-signalling pathway, which causes expression of FFly luciferase gene. Luciferase activity is quantitatively assessed by detection of bioluminescence. Working concentration values (2.5 ng/ml) and time of performing the assay (8 h) were chosen. The effectiveness of using the model system for testing IFN-y bioactivity has been shown.

интерферон-гаммабиоактивностьтест-системаinterferon-gammabioactivitytest systemBufe A, Gehlhar K, Grage-Griebenow E, Ernst M. Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol. 2002;127(1):82-8.Larkin J 3rd, Ahmed CM, Wilson TD, Johnson HM. Regulation of interferon gamma signaling by supperessors of cytokine signaling and regulatory T cells. Fronties in Immunology. 2013;4(469):1-8.Valour F, Perpoint T, Senechal A, Kong XF, Bustamante J, Ferry T, et al. Interferon-γ autoantibodies as predisposing factor for nontuberculous mycobacterial infection. Emerg Infect Dis. 2016;22(6):1124-6.Panel of experts from the Mycobacteria Study Group (GEIM) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Respiratory Diseases and Thoracic Surgery (SEPAR), Santin M, Garcia-Garcia JM, Dominguez J. Guidelines for the use of interferon-y release assays in the diagnosis of tuberculosis infection. Enferm Infecc Microbiol Clin. 2016; 34(5):303.e1-303.e13.Selimova LM, Kalnina LB, Serebrovskaya LV, Ivanova LA, Gulyaeva AN, Nosik DN. Cytokines during the human immunodeficiency virus infection type 1(HIV-1). Vopr Virusol. 2016;61(1):39-41.Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41-101.Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-21.Общая фармакопейная статья «Биологические методы испытания препаратов интерферона с использованием культур клеток». М. з. РФ.Михайлова ИН, Барышников АЮ, Морозова ЛФ, Бурова ОС, Демидов ЛВ, Палкина ТН и др. Клеточная линия меланомы человека mel P, используемая для получения противоопухолевых вакцин. Патент на изобретение RUS 2287575, 22.04.2005.Михайлова ИН, Лукашина МИ, Барышников АЮ, Морозова ЛФ, Бурова ОС, Панкина ТН и др. Клеточные линии меланомы - основа для создания противоопухолевых вакцин. Вестник Российской академии медицинских наук. 2005;7:37-40.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-5.Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. 1982.